Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › IL-2Rβ-selective agonists in combination with an anti-CTLA-4 antibody or an anti-PD-1 antibody

IL-2Rβ-selective agonists in combination with an anti-CTLA-4 antibody or an anti-PD-1 antibody

US Patent 10010587 · Granted Jul 3, 2018

Estimated economic value: $74,214,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Conjugates of an IL-2 moiety and a polymer2025
Combination of an IL-2RBETA-selective agonist and a long-acting IL-15 agonist2025
Antibodies and related molecules and uses thereof2023
Immunotherapeutic treatment method using an interleukin-2 receptor beta-selectiv2022
Conjugates of an IL-2 moiety and a polymer2021
Il-2Rβ-selective agonists in combination with an anti-CTLA-4 antibody or an anti2020
Il-2Rβ-selective agonists in combination with an anti-CTLA-4 antibody or an anti2020
Il-2Rβ-selective agonists in combination with an anti-CTLA-4 antibody or an anti2020
Il-2Rβ-selective agonists in combination with an anti-CTLA-4 antibody or an anti2020
Combination-based treatment method2020
Conjugates of an IL-2 moiety and a polymer2018
FGFR extracellular domain acidic region muteins2015